Meridian Bioscience Q4 Revenues Rise 6 Percent; MDx Business Continues to Grow | GenomeWeb

NEW YORK (GenomeWeb News) – Meridian Bioscience today said that its fiscal fourth-quarter sales rose 6 percent year over year with its molecular diagnostic business contributing to the growth.

For the three months ended Sept. 30, the company posted $43.7 million in revenues, compared to $41.3 million a year ago, beating the consensus analyst estimate of $43.0 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: statistical approach to examine intra-tumor heterogeneity, new genetic condition called otulipenia, and more.

Blood tests looking for biomarker changes could catch mental illnesses earlier, Newsweek reports.

DNA testing offers Korean adoptees a way to find their birth parents that sidesteps bureaucratic red tape, according to the New York Times.

A National Institutes of Health researcher has filed an Equal Employment Opportunity complaint against the agency, the Washington Post reports.